Cancer Research Institute Inc

SEE ON SCHEDULE OTHE CANCER RESEARCH INSTITUTE'S MISSION IS TO SAVE MORE LIVES BYFUELING THE DISCOVERY AND DEVELOPMENT OF POWERFUL IMMUNOTHERAPIES FORALL TYPES OF CANCER. TO ACCOMPLISH THIS, CRI FUNDS LABORATORY,TRANSLATIONAL, AND CLINICAL RESEARCH.

CLINICAL ACCELERATOR GRANTS PROGRAM - SEE SCHEDULE OTHE CRI ANNA-MARIA KELLEN CLINICAL ACCELERATOR : IS AN ACTIVELY MANAGED VENTURE PHILANTHROPY PROGRAM DESIGNED TO SPEED THE DEVELOPMENT OF PROMISING NEW CANCER IMMUNOTHERAPY COMBINATIONS. THIS MODEL FACILITATES RESEARCH COLLABORATION ACROSS LEADING BIOPHARMA COMPANIES AND THE CRI NETWORK OF IMMUNO-ONCOLOGY EXPERTS. THE PROGRAM INCLUDES PLATFORM CLINICAL TRIALS THAT ARE COLLABORATIVE, INTEGRATIVE, SCIENCE/DATA-DRIVEN, AND HYPOTHESIS-ANSWERING CLINICAL STUDIES. CRI PLANS, IMPLEMENTS, INVESTS IN, AND MANAGES EACH CLINICAL ACCELERATOR CLINICAL TRIAL AND WORKS CLOSELY WITH ACADEMIC RESEARCHER AND INDUSTRY PARTNERS ON SUCH STUDIES. EACH CLINICAL TRIAL AND PHILANTHROPIC INVESTMENT BRINGS A POTENTIAL NEW CANCER TREATMENT CLOSER TO PATIENTS, EMPOWERS ACADEMIC RESEARCHERS TO WORK MORE CLOSELY WITH INDUSTRY, AND CREATES A POTENTIAL RETURN ON INVESTMENT TO BE USED TO SUPPORT FURTURE CLINICAL EFFORTS.

CRI CLINICAL INNOVATOR:THE CRI CLINICAL INNOVATOR SUPPORTS NOVEL CLINICAL STUDIES THAT ADDRESS AREAS OF HIGH UNMET NEED IN CANCER AND SEEK MECHANISTIC INSIGHTS INTO CLINICAL RESPONSE WITH A GOAL OF PREDICTIVE BIOMARKER DISCOVERY. TO MAXIMIZE THE IMPACT OF EACH CLINICAL TRIAL, CRI WILL ADVISE ON SELECTED STUDIES IN A COORDINATED EFFORT TO OPTIMIZE CLINICAL TRIAL DESIGN AND TRANSLATIONAL STUDIES. FUNDING OF UP TO $1M PER TRIAL IS AWARDED.CLINIC AND LABORATY INTEGRATION PROGRAM (CLIP):THE CRI CLINIC AND LABORATORY INTEGRATION PROGRAM (CLIP) SUPPORTS PRE-CLINICAL AND TRANSLATIONAL RESEARCH THAT CAN BE DIRECTLY APPLIED TO OPTIMIZING CANCER IMMUNOTHERAPY IN THE CLINIC. CLIP GRANTS ARE AWARDED TO QUALIFIED SCIENTISTS EXPLORING CLINICALLY RELEVANT QUESTIONS AIMED AT IMPROVING THE EFFECTIVENESS OF CANCER IMMUNOTHERAPIES. CLIP GRANTS PROVIDE UP TO $300,000 OVER TWO YEARS. TECHNOLOGY IMPACT AWARD:THE CRI TECHNOLOGY IMPACT AWARD PROVIDES SEED FUNDING OF UP TO $200,000 TO BE USED OVER 24 MONTHS TO ADDRESS THE GAP BETWEEN TECHNOLOGY DEVELOPMENT AND CLINICAL APPLICATION OF CANCER IMMUNOTHERAPIES.CRI IMPACT GRANTS:CRI IMPACT GRANTS SUPPORT RESEARCH PROJECTS AND PUBLIC EDUCATION AND AWARENESS INITIATIVES WITHIN OR APPLICABLE TO THE FIELDS OF IMMUNOLOGY AND TUMOR IMMUNOLOGY FOR WHICH FUNDS HAVE BEEN SPECIFICALLY RAISED.

FELLOWSHIP PROGRAM - SEE SCHEDULE OTHE CRI POSTDOCTORAL FELLOWSHIP PROGRAM INCLUDES THREE TRACKS OF FELLOWSHIPS PROVIDING CAREER DEVELOPMENT, TRAINING, AND DIVERSITY BUILDING IN IMMUNOLOGY AND IMMUNO-INFOMATICS. THE CRI IRVINGTON POSTDOCTORAL FELLOWSHIP, CRI IRVINGTON POSTDOCTORAL FELLOWSHIP TO PROMOTE RACIAL DIVERSITY, AND THE CRI IMMUNO-INFORMATICS FELLOWSHIP EACH SUPPORT YOUNG IMMUNOLOGISTS AND CANCER IMMUNOLOGISTS AT TOP UNIVERSITIES AND RESEARCH CENTERS AROUND THE WORLD. FELLOWS RECEIVE UP TO $243,000 OVER THREE YEARS TO COVER THE COST OF STIPEND, INCLUDING AN INSTITUTIONAL ALLOWANCE TO HELP PAY FOR THE FELLOW'S RESEARCH SUPPLIES, TRAVEL TO SCIENTIFIC MEETINGS, HEALTH INSURANCE, AND/OR CHILDCARE. OF THE MORE THAN 1,550 CRI POSTDOCTORAL FELLOWS FUNDED TO DATE, MANY HAVE SINCE BECOME HEADS OF MAJOR MEDICAL RESEARCH INSTITUTES, ACADEMIC LEADERS IN PRESTIGIOUS UNIVERSITIES, AND ADMIRED MENTORS TO THE NEXT GENERATION OF IMMUNOLOGISTS AND TUMOR IMMUNOLOGISTS.

STAR PROGRAM - SEE SCHEDULE OTHE LLOYD J. OLD STAR PROGRAM, LAUNCHED IN 2019, PROVIDES GRANTS OF $1.25 MILLION OVER 5 YEARS TO MID-CAREER SCIENTISTS. THIS LONGTERM FUNDING IS NOT TIED TO A SPECIFIC RESEARCH PROJECT, BUT RATHER AIMS TO PROVIDE A DEGREE OF FLEXIBILITY AND FREEDOM FOR INVESTIGATORS TO EXPLORE OUTSIDE-THE-BOX AND DISRUPTIVE AVENUES OF RESEARCH. CANDIDATES SELECTED FOR THIS AWARD ARE EXPECTED TO BE FUTURE "STARS" IN THE FIELD OF CANCER IMMUNOLOGY: SCIENTISTS TAKING RISKS.